{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-094875","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.920440+00:00","generated_at":"2026-06-03T23:22:55.476692+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share","bullets":["10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.","Gross proceeds of $175M; net proceeds estimated at ~$164M after underwriting discounts and expenses.","Proceeds to fund clinical development, R&D pipeline expansion, and working capital.","Underwriters granted 30-day option to purchase up to an additional 1.75M shares.","Offering expected to close on or about April 16, 2024, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-094875","json":"https://secwatch.observer/filing/0001193125-24-094875.json","markdown":"https://secwatch.observer/filing/0001193125-24-094875.md","text":"https://secwatch.observer/filing/0001193125-24-094875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/0001193125-24-094875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/d818273d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:22:55.476692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f162d5ca548cc00e9b22fba238ba1691ecc27052","claim":"Nurix Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated valued at Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t (effective 2024-04-11).","evidence_excerpt":"On April 11, 2024, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, as the representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 10,166,667 shares of its common stock (the “Shares”) and (b) pre-funded warrants to purchase 1,500,100 shares of its common stock (the “Pre-Funded Warrants”) to the Underwriters (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/0001193125-24-094875-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated"},{"label":"Value","value":"Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t"},{"label":"Effective","value":"2024-04-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}